Cervical carcinomas are most frequently associated with human papillomaviruses (HPV), whose E6 and E7 oncogenes products induce cellular immortalization. The papillomavirus E2 protein is a transcription factor, which represses the expression of the viral oncogenes, and activates viral DNA replication during the vegetative viral cycle. This protein is specifically inactivated in HPV18-associated carcinoma cells, suggesting that E2 functions prevent carcinogenic progression. Indeed, ectopic expression of E2 in cervical carcinoma cells strongly inhibits cell proliferation. Here we show that above a threshold level of expression, the E2 protein induces apoptosis, independently of other viral functions. The amino-terminal domain is responsible for this apoptotic activity, but surprisingly with no involvement of its transcriptional functions. The death pathway triggered by E2 relies on activation of the initiator caspase 8, specific of the extrinsic pathway of apoptosis. E2 itself is cleaved by caspases during cell death, providing an example of an apoptotic inducer that is itself a target for caspase processing. The autonomous proapoptotic activity of HPV18 E2 described here may counteract the proliferative functions of viral oncogenes, and renders the inactivation of E2 crucial for carcinogenic progression.
Introduction
The great majority of cervical cancers are initiated by infection of high-risk human papillomaviruses (HPV), including HPV18. Carcinogenic initiation and maintenance of the malignant phenotype require the continuous expression of the viral oncogenes E6 and E7, whose activities perturb cell cycle controls. Concomitant expression of these proteins is sufficient to immortalize primary cells. The E6 protein targets p53 for proteasome-dependent degradation (Scheffner et al., 1990) and stimulates telomerase activity (Klingelhutz et al., 1996) , leading to abrogation of DNA damage check-points and escape from cellular senescence (Kiyono et al., 1998) . E7 neutralizes the retinoblastoma tumor suppressor pathway (Mu¨nger et al., 2001) . Both proteins also increase genomic instability (Duensing et al., 2000) , favoring accumulation of mutations required for the progression of immortalized cells toward tumorigenesis. In HPVassociated cervical carcinoma, the viral genome is usually integrated into the host chromosome, with loss of the gene encoding the viral E2 protein (Corden et al., 1999) .
The E2 protein of papillomaviruses is a regulatory protein playing crucial roles during the vegetative viral cycle. It acts as a regulator of the transcription of viral oncogenes, and as an activator of viral DNA replication in combination with the E1 helicase (Desaintes and Demeret, 1996) . The HPV18 E2 protein is a potent transcriptional activator when bound upstream of minimal promoters (Thierry et al., 1990) . However, in the context of the viral genome, it acts predominantly as a repressor of the transcription of the viral oncogenes E6 and E7, ensuring their controlled expression (Thierry and Yaniv, 1987) . As the function of E2 is lost in most HPV-associated cervical carcinomas, its selective inactivation was hypothesized to be a key step in the carcinogenic progression associated with HPV. Indeed, E2 has been shown to exhibit antiproliferative properties when ectopically expressed in Hela cells, which are associated with HPV18, inducing either a G1 growth arrest or cell death by apoptosis (Desaintes et al., 1997; Dowhanick et al., 1995; Hwang et al., 1993) . The G1 arrest is because of E2-mediated transcriptional repression of the resident E6 viral oncogene, which induces stabilization of p53, and results in p21 transcriptional activation. In contrast, apoptosis does not coincide with p53 activation (Desaintes et al., 1999) , suggesting that the proapoptotic function of E2 might be independent from transcriptional repression of the viral oncogenes.
To test this assumption, we studied the induction of apoptosis by HPV18 E2 in a variety of cells, either associated with human genital papillomaviruses or not. Using a panel of recombinant adenoviruses expressing either wild-type or mutated versions of the HPV18 E2 protein, fused to the green fluorescent protein (gfp), we detected the proapoptotic activity of E2 in all cells tested, without any requirement for other viral functions. Apoptosis occurred at a threshold level of E2, which remained significantly lower than the levels achieved when E2 was deleted of its amino-terminal domain. The transactivation domain was responsible for induction of apoptosis, which was however independent of E2 transcriptional activity. In cervical carcinomaderived cells, the G1 arrest, because of E2-mediated repression of viral oncogenes transcription, protected cells from further induction of apoptosis. E2-mediated apoptosis was dependent on caspase activation, and was mainly initiated by caspase 8. Finally, we found that E2 was itself cleaved by caspases during the death process, providing an example of an apoptotic inducer which is itself a substrate for caspase processing.
Results

HPV18 E2, expressed from recombinant adenoviruses, induces apoptosis independently of other viral functions
We have previously shown that expression of the fulllength HPV18 E2 protein, but not a mutant lacking the transactivation domain (TAD), induced apoptosis in the HPV18-associated Hela cells (Desaintes et al., 1997 (Desaintes et al., , 1999 . To further characterize this proapoptotic activity, we constructed recombinant adenoviruses expressing the E2 protein from HPV18, either full-length or deleted of the transactivation domain (del TAD), fused to the gfp (Figure 1a) . The gfp moiety allowed detection of E2 or of its truncated form in living cells, without altering their biological properties (Bellanger et al., 2001) .
We first infected a series of human cell lines derived from various HPV-associated cervical carcinomas. Cells were infected with recombinant adenoviruses expressing the gfp-E2, gfp-del TAD, or gfp alone, at a multiplicity of infection (m.o.i.) that induced expression of gfpfusion proteins in all the cells between 24 and 48 h postinfection. The m.o.i. used were adapted to each cell type, since sensitivity to adenoviral infection was variable. Cell death was assessed by analysis of the DNA content by flow cytometry, using sub-2N fraction as a measure of apoptosis. The gfp-E2 protein was shown to induce apoptosis in both HPV18-associated Figure 1b ). In the presence of gfp-delTAD or gfp alone, the sub-2N fraction was variable (Figure 1b) , but was similar to the basal level of apoptosis for each cell type (data not shown).
When analysed with a variety of HPV-negative human cells, E2-induced apoptosis was shown to occur systematically, indicating that the proapoptotic activity of E2 is independent of other viral functions and of the cell type (Figure 1c ). Of note is the susceptibility to E2-induced apoptosis of Saos cells, which do not express any p53 protein, thus establishing that E2 triggers an apoptotic pathway independent of p53.
A threshold level of E2 is required to induce apoptosis Figure 2b ). However, the levels of gfp-E2 always remained below those of gfpdelTAD, while the gfp alone accumulated at least five times more (not shown). Overexpression of gfp fusion proteins per se is therefore not responsible for cell death. In contrast, the threshold level above which gfp-E2 is not tolerated can be clearly exceeded by gfp-del TAD or gfp, meaning that overexpression of E2 in the cells is not allowed. It should be noted that the full-length E2 protein can hardly accumulate in the cells because of its high instability. The flow cytometric analysis of gfp fluorescence, reflecting the levels of gfp-E2, versus DNA content, in Ad gfp-E2 infected cells confirmed the existence of a threshold level of gfp-E2, above which the sub-2N DNA fraction started to accumulate ( Figure 2c ). These results indicated that cells expressing E2 above this threshold level are eliminated by apoptosis. A video recording of Saos cells infected by Ad gfp-E2 indicated that cells started to die at high frequency after a time lag of 16-18 h postinfection, during which the level of gfp fluorescence increased (not shown).
The amino-terminal domain of E2 is sufficient to induce apoptosis independently of its transcriptional functions
The truncated version of the HPV18 E2 protein, in which the transactivation domain was deleted, did not induce apoptosis, suggesting that the transactivation domain is required for the proapoptotic activity. To test whether this domain of E2 was sufficient to induce apoptosis, we constructed a recombinant adenovirus expressing the transactivation domain of E2, fused to the gfp and to the nuclear localization signal of the SV40 TAg ( Figure 1a , gfp-TAD). The gfp-TAD protein efficiently induced apoptosis, indicating that the TAD alone was responsible for the proapoptotic activity of the protein (Figure 3a) . In HeLa cells, gfp-TAD proved to be even more efficient than the full-length protein for death induction (Figure 3a) , whereas it did not induce a G1 cell cycle arrest, in contrast to full-length E2 (Figure 3b ). In Saos-2 cells, both gfp-E2 and gfp-TAD induced apoptosis at similar levels (Figure 3a) , and neither protein arrested the cell cycle in G1 (Figure 3b ). These results indicated that E2-induced G1 arrest, because of the repression of viral oncogenes transcription in HeLa cells, protected against induction of apoptosis, suggesting that these two functions of E2 are mutually exclusive.
We wondered whether transcriptional activation could be involved in the proapoptotic activity of E2, Triggering of the extrinsic apoptotic pathway by HPV18 E2 C Demeret et al as it has generally been shown for transcription factors triggering apoptosis. To address this question, we made use of various point mutants of E2 proteins defective for transcription. The E2 I77A protein was mutated in the TAD domain and was defective for activation of transcription when tested on synthetic promoters, as previously described (Desaintes et al., 1999) . In addition, we constructed an E2 protein containing mutations L299S-R305K in the DNA binding domain, which was unable to bind DNA, as detected by gel retardation (not shown). These two mutated E2 proteins were expressed as gfp-fusion proteins from recombinant adenoviruses, and their proapototic activities were analysed. Both I77A and L299S-R305K mutant induced apoptosis in Saos-2 and HeLa cells, with efficiencies similar to gfp-E2 (Figure 3c and data not shown), indicating that E2 induced apoptosis independently of its transcriptional functions.
E2-mediated apoptosis depends on caspase 8 activation
To determine whether E2-mediated apoptosis was caspase-dependent, we treated Ad gfp-E2-infected cells with the pan-caspase inhibitor Z-VAD-FMK. Inhibition of caspases abolished E2-mediated apoptosis, indicating its dependence on caspase activation (Figure 4a) . We checked the involvement of initiator caspases 8 or 9 by using specific inhibitors. The caspase 8 inhibitor Z-IETD-FMK strongly interfered with E2-mediated apoptosis (Figure 4b ), suggesting that caspase 8 is the initial caspase activated during E2-induced apoptosis. Indeed, we observed cleavage of caspase 8 in dead cells, Triggering of the extrinsic apoptotic pathway by HPV18 E2 C Demeret et al which was inhibited by Z-VAD-FMK (Figure 4c ). In contrast, we failed to detect any activated/cleaved caspase 9 in extracts of dead cells (not shown), despite the two-fold reduction of apoptotis observed in vivo in the presence of the caspase 9 inhibitor Z-LEHD-FMK (Figure 4b ).
Full-length E2 protein is a substrate for caspase processing
When we examined the level of expression of gfp-E2 protein in dead cells compared to living cells, we observed that the full-length protein was strongly reduced in dead cells, while proteolytic cleavage products became predominant (Figure 5a ). A major proteolytic fragment was detected specifically by an anti-E2 antibody (designed as P1), whereas a lower molecular weight fragment P2 was detected by both anti-gfp and anti-E2 antibodies (Figure 5a ). In the presence of Z-VAD FMK, the proteolytic cleavage of gfp-E2 was markedly reduced. In contrast, the proteolytic pattern of gfp-delTAD did not differ whether or not the cells were treated with Z-VAD FMK (Figure 5b ). The search for putative caspase recognition motives XEXD in the amino-terminal transactivation domain of E2 revealed a single putative site, 22 residues from the initiator methionine (Figure 5c ). The cleavage of the gfp-E2 fusion protein at this site would generate fragments with predicted molecular weights of 31.8 and 38.3 kDa, respectively, which is consistent with the predominant cleavage pattern observed in apoptotic cells thus suggesting use of this site for caspase digestion.
Discussion
The use of recombinant adenoviruses expressing wild-type or mutated versions of the HPV18 E2 protein, Triggering of the extrinsic apoptotic pathway by HPV18 E2 C Demeret et al fused to gfp, allowed us to carry out a comprehensive analysis of the susceptibility of various cell types to E2-mediated cell death. We observed proapoptotic activity of the HPV18 E2 protein in all cells tested and this activity was independent of any other viral genes. E2-induced apoptosis occurred regardless of the transformed state of the cells, indicating that it does not require deregulated proliferation or survival pathways.
The involvement of p53 in E2-induced apoptosis has been controversial. The apoptosis induced by the HPV18 E2 has been shown to occur independently of p53 transcriptional activity (Desaintes et al., 1999) ; however, it remained unclear whether transcriptionalindependent functions of p53 contributed to this apoptosis. The present finding that Saos-2 cells, whose p53 gene is disrupted, were sensitive to the apoptotic activity of E2 firmly establishes that HPV18 E2-induced apoptosis occurs independently of any functions of the p53 protein. This result contrasts with a recent report of Gaston's group (Webster et al., 2000) showing that the apoptotic activity of HPV16 E2 depends on p53. The reasons for this discrepancy may reside in the way that the E2 proteins were delivered to the cells, infection with recombinant adenoviruses allowing the expression of gfp-E2 protein to comparable levels in a large variety of cell types. However, we cannot exclude that the E2 proteins from the HPV types 16 and 18 may use different mechanisms to induce apoptosis.
Several studies have described the effects of the E2 proteins on cell proliferation. E2 was shown to abrogate cell proliferation of HPV-associated carcinoma cells, because of the transcriptional repression of the resident viral oncogenes (Desaintes et al., 1997; Dowhanick et al., 1995; Hwang et al., 1993) . The growth inhibition culminates in replicative senescence (Goodwin et al., 2000; Wells et al., 2000) . We and others described the induction of apoptosis by E2 independently of the transcription of the viral oncogenes (this study, Desaintes et al., 1999; Webster et al., 2000) . The effects of E2 on cell proliferation are therefore multiple, the consistent physiological outcome being to block cell proliferation. The expression of viral oncogenes, as well as the levels of E2 protein, probably dictate cell fate upon E2 expression. We demonstrated in this study that induction of G1 growth arrest by the full-length E2 protein in HeLa cells interfered with induction of apoptosis. This suggests that commitment to replicative senescence program would prevent further induction of apoptosis.
We think that the proapoptotic activity of E2 may be relevant to the vegetative viral cycle, which is closely linked to differentiation of the infected keratinized epithelia. We propose that E2 accumulates in the course of keratinocyte differentiation, allowing viral genome amplification in the presence of the E1 helicase, and triggering apoptosis after a threshold level is reached. In fact, keratinocyte differentiation involves a process related to apoptosis, with activation of caspases and subsequent DNA fragmentation and nuclear loss (Weil et al., 1999) . However, this specific process differs from classical apoptosis because dead keratinocytes are maintained in a cornified layer rather than being eliminated. This natural cell death process may impair efficient virus release. The proapoptotic activity of E2 would divert the terminal differentiation program of keratinocytes towards more classical apoptosis, which would result in cell breakage and facilitate virus release. Our model is corroborated by the detection of E2 in the upper layers of HPV16-associated benign lesions (Maitland et al., 1998) .
Apoptosis induced by E2 was initiated by activation of caspase 8, involved in the 'death receptors ' or 'extrinsic' pathway (Ashkenazi and Dixit, 1998) . To our knowledge, most transcription factors that trigger caspase-8-initiated apoptosis modify the transcription of players of the extrinsic pathway. In this respect, it is surprising that the HPV18 E2 protein acts through this death pathway independently of transcriptional transactivation, as we have shown in this study. We propose that E2 induces apoptosis by direct interaction of its amino-terminal domain with factors involved in the caspase-8-initiated apoptotic pathway, which would constitute a novel strategy for a transcription factor to trigger apoptosis. As E2 stability is regulated by the proteasome pathway, another possibility would be that overexpression of E2 saturates the cellular degradation machinary, leading to deregulation of important cellular functions and subsequent apoptosis. Indeed, the half-life of E2 was increased five times when overexpressed (results not shown), and the fact that a threshold level of E2 was required for induction of apoptosis fits well with this hypothesis. However, more work is needed to determine whether E2 causes apoptosis by inhibition of the proteasome pathway, or has intrinsic cytotoxic effects.
We observed that the E2 protein was itself cleaved by a caspase, whose identity remains to be established. Indeed, a putative caspase recognition motif XEXD (Thornberry et al., 1997) was found in the transactivation domain of the protein, localized at the end of the first a helix. Interestingly, the XEXD box is conserved among the E2 proteins of high-risk genital papillomaviruses, but not of low-risk papillomaviruses HPV types 6 or 11. According to the crystal structure of the transactivation domain of HPV16 E2 (Antson et al., 2000) , this motif is exposed at the surface of the protein, rendering it accessible to digestion by caspases. Caspase cleavage at this site would generate a truncated protein lacking transcriptional and replicative activities, but still able to bind to the viral genome. Caspase targets are either apoptotic effectors or regulators (Wolf and Green, 1999) . On the other hand, transcription factors known to be proteolytically inactivated by caspases are activators of survival or proliferative genes, such as NFKB or SRF (Drewett et al., 2001; Levkau et al., 1999) . To our knowledge, however, there are no reported examples of inducers of apoptosis that are by themselves cleaved by caspases, as we have shown here for the HPV18 E2 protein. Elucidation of the relationship between initiation of apoptosis and caspase cleavage of HPV18 E2 may uncover new mechanisms of apoptotic induction.
To date, the E2 protein has been described as a key regulator of viral processes, such as transcription or viral DNA replication. In the present study, we show that it is also a direct modifier of the cellular physiology, opening new perspectives for the understanding of its role in the viral vegetative cycle. During malignant progression associated with HPV, E2 loss of function would not only preclude repression of the transcription of viral oncogenes, but would also allow cells to escape death.
Materials and methods
Cells and infection
Dubelcco's modified Eagles's medium (DMEM) supplemented with fetal calf serum was used to maintain cell lines. Primary human foreskin keratinocytes were maintained in keratinocyte-SFM medium (KGM, Gibco BRL) complemented with EGF and bovine pituitary extract. HPV18-transformed keratinocytes (HK18) were grown in a medium containing 3/4 KGM and 1/4 DMEM 7% fetal calf serum. Infections were done on 50-80% confluent cells, 24 h after plating, for 1 h at 371C. When indicated, Z-VAD-FMK (40 mm, Biomol), Z-IETD-FMK or Z-LEHD-FMK (100 mm, Calbiochem) were added immediately after infection.
Virus construction and production
Wild-type or truncated versions of gfp-E2 fusion proteins were prepared from the pEgfp-derived expression plasmids previously described (Bellanger et al., 2001) . The E2 I77A mutant was previously described (Desaintes et al., 1999) . Mutations S299L-R305K were introduced in the E2 ORF by conventional PCR-based mutagenesis. Expression cassettes of the various gfp-fusion proteins were introduced in place of the E1A-E1B region in replication-deficient recombinant adenoviruses, by a two-step procedure in bacteria as described previously (Crouzet et al., 1997) . Recombinant adenoviruses were produced and amplified in 293-A cells. Viruses were subsequently purified on CsCl gradients, and titrated. Adenovirus expressing the gfp alone was purchased from Quantum.
Flow cytometry
Cells were harvested between 24 and 48 h postinfection, washed once with PBS, and fixed in ice-cold 701 ethanol. In some cases, cells were treated with 100 mm Na 2 HPO 4 and 2 mm citric acid for 15 min, to favor extraction of low molecular weight DNA (Darzynkiewicz et al., 1994) . DNA was stained with propidium iodide (20 mg/ml) plus 10 mg/ml RNase for 30 min, and analyzed with epics XL FACS (Coulter).
Immunoprecipitation and immunodetection
Gfp-fusion proteins were immunoprecipitated from total cellular proteins prepared in 0.5 m sucrose, 15 mm Tris-HCl pH 7.5, 400 mm KCl, 0.25 mm EDTA, 0.125 mm EGTA, 0.5 mm spermine, 0.15 mm spemidine, 1 mm DTT and a mixture of protease inhibitors (Boehringer). After dilution to 250 mm salt, proteins were precleared with 5 ml of an irrelevant rabbit immunoserum in the presence of 25 ml protein Asepharose for 2 h. Proteins were then incubated with 5 ml of a rabbit polyclonal immunoserum prepared against the carboxyterminal part of the E2 protein, and incubated overnight at 41C, and 25 ml of protein A-sepharose was added for 1 h. After extensive washes in extraction buffer containing 250 mm KCl, protein A beads were incubated in Laemmli buffer, boiled, and loaded to a polyacrylamide gel for separation.
Immunodetection was performed using either immunoprecipitated proteins or total cellular proteins, loaded at equivalent amounts. The antibodies used were mouse monoclonal anti-gfp antibody (Chemicon), rabbit polyclonal anti-E2 antibodies directed against the full-length protein, rabbit polyclonal anti-actin (Sigma), and rabbit polyclonal anticaspase 8 (Pharmingen).
